Protective effect of Bacillus anthracis surface protein EA1 against anthrax in mice

Biochemical and Biophysical Research Communications

Volumn 421, Issue 2, 2012, Pages 323-328

  Uchida, Makoto ^a   Harada, Toshihiko ^a   Enkhtuya, Jargalsaikhan ^a   Kusumoto, Akiko ^a   Kobayashi, Yoshiyasu ^a   Chiba, Shiori ^a   Shyaka, Anselme ^a   Kawamoto, Keiko ^a  

^a OBIHIRO UNIVERSITY OF AGRICULTURE AND VETERINARY MEDICINE   (Japan)

Author keywords

Anthrax; EA1; Mucosal immunization; Vaccine

Indexed keywords

ANTHRAX VACCINE; ANTIBODY; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; PROTECTIVE ANTIGEN; RECOMBINANT EXTRACTABLE ANTIGEN 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBODY PRODUCTION; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL SPORE; CONTROLLED STUDY; FECES; IMMUNIZATION; INFECTION PREVENTION; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SALIVA; SERUM;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; MALE; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS;

BACILLUS ANTHRACIS; MUS;

EID: 84860452521     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.04.007     Document Type: Article

References (31)

1. Dixon T.C., Meselson M., Guillemin J., et al. Anthrax. New England Journal of Medicine 1999, 341:815-826.
2. Young J.A., Collier R.J. Anthrax toxin: receptor binding, internalization, pore formation, and translocation. Annual Review of Biochemistry 2007, 76:243-265.
3. Tournier J.N., Ulrich R.G., Quesnel-Hellmann A., et al. Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis. Expert Rev Anti Infect Ther 2009, 7:219-236.
4. Marano N., Plikaytis B.D., Martin S.W., et al. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. Jama 2008, 300:1532-1543.
5. Whiting G.C., Rijpkema S., Adams T., et al. Characterisation of adsorbed anthrax vaccine by two-dimensional gel electrophoresis. Vaccine 2004, 22:4245-4251.
6. Mock M., Fouet A. Anthrax. Annu Rev Microbiol 2001, 55:647-671.
7. Bhalla D.K., Warheit D.B. Biological agents with potential for misuse: a historical perspective and defensive measures. Toxicol Appl Pharmacol 2004, 199:71-84.
8. Cohen S., Mendelson I., Altboum Z., et al. Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax. Infect Immun 2000, 68:4549-4558.
9. Mesnage S., Tosi-Couture E., Mock M., et al. Molecular characterization of the Bacillus anthracis main S-layer component: evidence that it is the major cell-associated antigen. Mol Microbiol 1997, 23:1147-1155.
10. Fouet A., Mesnage S., Tosi-Couture E., et al. Bacillus anthracis surface. capsule and S-layer. J Appl Microbiol 1999, 87:251-255.
11. Delvecchio V.G., Connolly J.P., Alefantis T.G., et al. Proteomic profiling and identification of immunodominant spore antigens of Bacillus anthracis, Bacillus cereus, and Bacillus thuringiensis. Appl Environ Microbiol 2006, 72:6355-6363.
12. Redmond C., Baillie L.W., Hibbs S., et al. Identification of proteins in the exosporium of Bacillus anthracis. Microbiology 2004, 150:355-363.
13. Lai E.M., Phadke N.D., Kachman M.T., et al. Proteomic analysis of the spore coats of Bacillus subtilis and Bacillus anthracis. J Bacteriol 2003, 185:1443-1454.
14. Liu H., Bergman N.H., Thomason B., et al. Formation and composition of the Bacillus anthracis endospore. J Bacteriol 2004, 186:164-178.
15. Uchida I., Makino S., Sasakawa C., et al. Identification of a novel gene, dep, associated with depolymerization of the capsular polymer in Bacillus anthracis. Mol Microbiol 1993, 9:487-496.
16. Enkhtuya J., Kawamoto K., Kobayashi Y., et al. Significant passive protective effect against anthrax by antibody to Bacillus anthracis inactivated spores that lack two virulence plasmids. Microbiology 2006, 152:3103-3110.
17. Sinha K., Bhatnagar R. GroEL provides protection against Bacillus anthracis infection in BALB/c mice. Mol Immunol 2010, 48:264-271.
18. Ezzell J.W., Abshire T.G. Immunological analysis of cell-associated antigens of Bacillus anthracis. Infect Immun 1988, 56:349-356.
19. Zhang Y., Qiu J., Zhou Y., et al. Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses. Vaccine 2008, 26:614-622.
20. Love T.E., Redmond C., Mayers C.N. Real time detection of anthrax spores using highly specific anti-EA1 recombinant antibodies produced by competitive panning. J Immunol Methods 2008, 334:1-10.
21. Wang D.B., Yang R., Zhang Z.P., et al. Detection of B. anthracis spores and vegetative cells with the same monoclonal antibodies. PLoS One 2009, 4:e7810.
22. Williams D.D., Turnbough C.L. Surface layer protein EA1 is not a component of Bacillus anthracis spores but is a persistent contaminant in spore preparations. J Bacteriol 2004, 186:566-569.
23. Swiecki M.K., Lisanby M.W., Shu F., et al. Monoclonal antibodies for Bacillus anthracis spore detection and functional analyses of spore germination and outgrowth. J Immunol 2006, 176:6076-6084.
24. Welkos S., Little S., Friedlander A., et al. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 2001, 147:1677-1685.
25. Hahn U.K., Boehm R., Beyer W. DNA vaccination against anthrax in mice-combination of anti-spore and anti-toxin components. Vaccine 2006, 24:4569-4571.
26. Brossier F., Levy M., Mock M. Anthrax spores make an essential contribution to vaccine efficacy. Infect Immun 2002, 70:661-664.
27. Gauthier Y.P., Tournier J.N., Paucod J.C., et al. Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax. Infect Immun 2009, 77:1197-1207.
28. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006, 6:148-158.
29. Jertborn M., Nordstrom I., Kilander A., et al. Local and systemic immune responses to rectal administration of recombinant cholera toxin B subunit in humans. Infect Immun 2001, 69:4125-4128.
30. Ichinohe T., Watanabe I., Ito S., et al. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol 2005, 79:2910-2919.
31. Stern E.J., Uhde K.B., Shadomy S.V., et al. Conference report on public health and clinical guidelines for anthrax. Emerg Infect Dis 2008, 14.